No new areas of hypokinesis on cine CMR New LGE after PCI New LGE after PCI.

Slides:



Advertisements
Similar presentations
Clinical Trial Results. org ABSORB Presented at the American College of Cardiology Annual Scientific Session March, 2007 Presented by Dr. Patrick W. Serruys.
Advertisements

Challenges from Drug Eluting Stent (DES) Studies - Future DES Study Design Peter S. Lam, Ph.D. Director, Biostatistics, Medical Sciences.
 An angiographic tool grading the complexity of coronary artery disease  A semiquantitative visual score that will help us to be aware of the anatomical.
Www. Clinical trial results.org  Major Endpoints: Death, MI, stent thrombosis, TLR, TVR, MACE, and CKMB >3x nl  Major Endpoints: Death, MI, stent thrombosis,
Troponin I elevation as a marker of right ventricular dysfunction and severity in pulmonary embolism Background : 1.Cardiac troponin I (Ti) : a specific.
Paul Gurbel, Kevin Bliden, Tania Gesheff, Yvonne Kreutz, Udaya Tantry Sinai Center for Thrombosis Research Sinai Hospital of Baltimore Baltimore, Maryland,
FAME 2 year Objective:To investigate the 2-year outcome of PCI guided by FFR in patients with multivessel CAD. Study:Multicenter, single blind, randomized.
Randomized Comparison of FFR-guided and Angiography-guided Provisional Stenting for True Coronary Bifurcation Lesions: The DKCRUSH-VI trial Shao-Liang.
29th ANNUAL SCIENTIFIC SESSIONS – SCA&I
Raising the standard in treating bifurcation lesions GENNARO SARDELLA MD, FACC,FESC O.U. of Interventional Cardiology Dept. of.
$100 Area of Parallelograms Area of Triangles Perimeter And Area Area of Trapezoids Area of Compound Figures & Area and Circumference of Circles $200.
FFR in specific circumstances Zsolt Piróth MD Gottsegen György Hungarian Institute of Cardiology.
Jeffrey J. Popma, MD Alexandra Almonacid, MD
Klinikum Rosenheim Department of Diagnostic and Interventional Radiology LINC 2014 DEFINITIVE AR Severe Ca++ Arm 30-Day Results Gunnar Tepe, MD On behalf.
Subacute Occlusion at distal Edge of Stent Beijing Anzhen Hospital Capital Medical University Wu, Xiaofan.
Tips and Pitfalls in Measurement of FFR during Bifurcation Stenting Nanjing first hospital Nanjing cardiovascular hospital Yefei Chenshaoliang Zhangjunjie.
PET in Colorectal Cancer. Indications for FDG PET Rising marker, (-) CT/MRI Nonspecific findings on CT/MRI, recurrence or post treatment changes? Known.
SPIDER Saphenous Vein Graft Protection In a Distal Embolic Protection Randomized Trial Simon R. Dixon MBChB, William W. O’Neill MD William Beaumont Hospital,
Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty Study (ARMYDA-2) Trial ARMYDA-2 Trial Presented at The American College of Cardiology.
When I Use IVUS Neal Uren MD FRCP Consultant Cardiologist Royal Infirmary Edinburgh.
A AMI PATIENT WITH VERY VERY LATE THROMBOSIS IN THE STENT 极极晚期支架内血栓致急性心肌梗死 1 例 DEPARTMENT OF CARDIOLOGY OF GENERAL HOSPITAL OF CHINESE PEOPLE’S ARMED POLICE.
SIROLIMUS-ELUTING STENTS EFFECTIVELY INHIBIT NEOINTIMAL PROLIFERATION AS COMPARED TO BARE METAL STENTS IN DISEASED SAPHENOUS VEIN GRAFTS: 6-month IVUS.
A Randomized Comparison of Everolimus-­ Eluting Absorb Bioresorbable Vascular Scaffolds vs. Everolimus-Eluting Metallic Stents: One-Year Angiographic and.
FRONTIER Registry The Guidant MULTI-LINK FRONTIER ™ Coronary Stent System for the Treatment of Pts with Native De Novo or Restenotic Bifurcation Coronary.
LM strategy Interventional cardiology dpt Cardiovascular Hospital - Lyon - France Gilles Rioufol MD PhD INSERM U1060 High Tech Marseille, 26 Janvier 2012.
British Bifurcation Coronary Study Objective:To compare the outcome of 2 treatment strategies for bifurcation lesions. Study:Multicenter, randomized trial.
STATINS PRE-PCI: A Prospective, Randomized Trial of Statins Prior to Stent Implantation in Patients with Stable Angina Josef VESELKA CardioVascular Center.
TCT 2012 Revascularization Strategies for Complex Left Main Disease and Left Coronary Ostial Disease Alfredo E. Rodriguez, MD, PhD, FACC, FSCAI Centro.
PRevEntion of cardiac and Vascular pEriprocedural complications in patients undergoiNg coronary angiography or angioplasTy: IntraCoronary Adenosine administration.
Name of the speaker: Germano DiSciascio I have the following potential conflicts of interest to report:  Consulting  Employment in industry  Stockholder.
Case report of FFR for bifurcation Nanjing first hospital Nanjing heart center Yefei chenshaoliang.
Treatment of bifurcation lesions is a complex problem Different techniques are commonly used (Y-/T-stenting, „culotte“ technique, „kissing stent“ technique…)
Endeavor 4: A Randomized Comparison of a Zotarolimus- Eluting Stent and a Paclitaxel- Eluting Stent in Patients with Coronary Artery Disease Martin B.
Allen Jeremias, Neal Kleiman, Deborah Nassif, Wen-Hua Hsieh, Michael Pencina, Kelly Maresh, Manish Parikh, Donald Cutlip, Ron Waksman, Steven Goldberg,
The SAFER Trial Evaluation of the Clinical Safety and Efficacy of the PercuSurge GuardWire in Saphenous Vein Graft Intervention As presented at TCT 2000.
Date of download: 5/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: Incidence and Short-Term Clinical Outcomes of Small.
Date of download: 6/24/2016 Copyright © The American College of Cardiology. All rights reserved. From: Elevated Plasma Fibrinogen Rather Than Residual.
The reading is 7.38 mm. The reading is 7.72 mm.
Philippe Généreux, MD for the Tryton Bifurcation Trial Investigators Columbia University Medical Center Cardiovascular Research Foundation New York City.
End points in PTCA trials. A successful angioplasty is defined as the reduction of a minimum stenosis diameter to
Disrupt CAD Study Design
Cutting Edge Case Presentation #1
Nico H.J. Pijls, William F. Fearon, Peter Jüni, and Bernard De Bruyne
Clinical Usefulness of Post-Stenting FFR
BRANCH Bare Metal BifuRcAtion SteNt Clinical Trial in Humans Early Clinical Experience by Raoul Bonan, MD On behalf of the BRANCH study investigators.
Tubular LMS stenosis. LCx ostial stenosis
The Tryton Bifurcation Trial:
OCT-Guided PCI What needs to be done to establish criteria?
Additional file 2: Figure S1
Interesting Case Review
Topic: How do we calculate percent deviation?
The ASSERT Study.
Fig. 3. After BVS implantation
SIRIUS Trial: Diameter Restenosis
تحليل الحساسية Sensitive Analysis.
Atorvastatin for Reduction of Myocardial Damage During Angioplasty
Giuseppe Biondi Zoccai, MD
ENDEAVOR IV: 5 Year Final Outcomes
Bifurcation Disease: Simulation Training Curriculum
Significance of Periprocedural Myocardial Infarctions in Percutaneous Coronary Interventions A New Look at an Old Topic Abhiram Prasad, MD, FRCP, FESC,
(a) Dyslipidaemia (b) Final MLD P = P = P = 0.972
NEW GENERATION STENT COBALT-CHROMIUM SIROLIMUS ELUTING STENT.
TAXUS – Myonecrosis and sidebranch patency concerns are short-term issues with no long-term consequences, and the benefits are undeniable Jeffrey J. Popma,
12-month clinical and 13-month angiographic outcomes from a randomized trial evaluating the Absorb Bioresorbable Vascular Scaffold vs. metallic drug-eluting.
Fig. 6 ROC curves of mCCNA1 and mVIM assayed on esophageal balloon samplings of the distal esophagus. ROC curves of mCCNA1 and mVIM assayed on esophageal.
Five-minute parameter of thromboelastometry is sufficient to detect thrombocytopenia and hypofibrinogenaemia in patients undergoing liver transplantation 
Fadi J. Sawaya et al. JCIN 2016;9:
MRI Hyperenhancement is Associated with Myonecrosis Following PCI
Detection of Hemodynamically Significant Coronary Stenosis: CT Myocardial Perfusion versus Machine Learning CT Fractional Flow Reserve Myocardial blood.
Presentation transcript:

No new areas of hypokinesis on cine CMR New LGE after PCI New LGE after PCI

LGE new and Tn/CK-MB increase - From 9 cases with LGE (2 patients did not have postprocedural TnI) 6 were detected with TnI assay – 63% diagnostic accuracy (TnI > 2x ULN). - No linear relationship between LGE mass and TnI amount - CK-MB was less sensitive for myonecrosis detection in comparison with TnI – 4 cases from 11 – 36% with increase >1xULN; BUT only 1 case >2x ULN (9%); - No linear relationship with LGE detected mass

TnI assay sensitivity for LGE detection AUC 83%, sensitivity 89%, specificity 56%, p =.026 for LGE detection, when TnI >.05ng/dl

Parameters associated with new LGE LGE new (+)LGE new (-)p – value* SB lesion length, mm5.31 ± ± SB ostial MLD post stenting, mm.59 ±.1.99 ± Distal Limb Diameter final, mm 2.93 ± ± MB MLD final, mm2.82 ± ± MB %DS final, %-2% ± 12%14% ± 5%.002 SB %DS post stenting, %74% ± 16%59% ± 16%.049 LDL, mg/dl88 ± 3655 ± Trig, mg/dl110 ± 2979 ± Creatinine, mg/dl1.1 ± ± TnI post stenting, ng/ml2.23 ± ± * p <.05 one sided Man – Whitney U-test

Association between post stent implantation SB MLD and LGE mass and percent from LV mass

ROC analysis for effects of SB MLD and SB %DS post stenting on periprocedural myonecrosis SB MLD <.78 mm post stenting reveals new LGE with sensitivity 50%, specificity 70%, p =.074, AUC 78%. SB %DS >71% post stenting reveals new LGE with sensitivity 60%, specificity 83%, p =.129, AUC 73%.